CMPF

CMPF is a drug-binding inhibitor which is also a constituent of urine. CMPF can inhibit specific T4 binding in serum by increasing the free concentration of direct competitors.

ChEBI: A furoic acid that is furan-3-carboxylic acid substituted by a methyl group at position 4, a propyl group at position 5 and a 2-carboxyethyl group at position 2. It is a potent uremic toxin that has been found to accumulate in human serum of patients with hronic kidney diseases.

3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), a major metabolite of furan fatty acids, is a uremic toxin (UT), excreted into the urine via organic,anion transporters under physiological conditions. It is mostly reported to be accumulated in chronic kidney disease (CKD) patients. Monitoring of CMPF may be important to predict organic anion transporting polypeptide (OATP)1B activity in CKD patients as studies have implicated a decreased trend in (OATP)1B activity in patients with this uremic toxin. It is also found to be in increased concentrations, for patients who progress from prediabetes to type 2 diabetes, patients with renal failure, polyunsaturated fatty acids with high-temperature cooking and subjects who consume fish or fish oil.